Lightbridge Corporation — Q2 2019 Form 10-Q
Reporting period: Three and six months ended June 30, 2019. Unaudited results; comparisons are to the corresponding 2018 periods unless noted.
Business context
Lightbridge is a pre-commercial nuclear-fuel technology developer focused on metallic fuel rods. Fuel development is conducted principally through Enfission, LLC, a 50/50 joint venture with Framatome. The company reported no revenue in either comparison period and discontinued its consulting business segment in 2018.
Financial performance and position
| Metric | Q2 2019 | Six months 2019 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $1.78 million | $4.06 million |
| Operating loss | $3.43 million | $6.65 million |
| Net loss | $3.31 million | $6.42 million |
| Net loss attributable to common stockholders | $3.48 million; $0.09 per share | $6.76 million; $0.19 per share |
| Cash used in operating activities | Not separately presented | $2.91 million |
| Cash used in investing activities | Not separately presented | $3.67 million |
| Cash from financing activities | Not separately presented | $2.92 million |
At June 30, 2019, cash and cash equivalents were $20.98 million, total assets $23.41 million, current liabilities $0.47 million, and working capital approximately $21.17 million. The company reported no debt or credit lines. With no revenue, conventional profit margins are not meaningful. Its $6.42 million six-month net loss included $3.26 million of equity-method losses from Enfission.
Changes versus prior period
- Q2 net loss narrowed by $0.21 million to $3.31 million; operating expenses fell 11%, mainly due to lower general and administrative costs.
- For the first half, net loss narrowed by $1.82 million to $6.42 million. General and administrative expenses declined 30%, while research and development expense was broadly flat.
- Six-month operating cash use improved to $2.91 million from $3.22 million. Investing cash use declined to $3.67 million from $5.36 million, principally reflecting lower Enfission contributions.
- The prior-year first-half results included $0.98 million of financing-cost write-offs and a $2.62 million deemed preferred-stock dividend. These items affect comparability; the deemed dividend is excluded from net loss but reduces net loss attributable to common stockholders.
- Cash declined $3.66 million from year-end 2018. Common shares outstanding rose to 37.61 million from 32.86 million; the filing lists 47.58 million shares and common-stock equivalents, including options, warrants, convertible preferred shares, and accrued preferred dividends.
Outlook, risks, and unusual items
- Management said available resources were sufficient for its current 12-month operating budget from the financial-statement issuance date, while acknowledging recurring losses and expected negative cash flows for the foreseeable future. It cited approximately $9.3 million of expected general and administrative and corporate R&D outlays over 12 months, plus $6 million to $8 million for fuel R&D and approximately $3 million of R&D equipment capital expenditures over 12 to 15 months.
- Management expects continued investment in Enfission. Lightbridge had contributed approximately $9.1 million through June 30, compared with Framatome’s approximately $2.9 million. Enfission had about $1.5 million cash and recorded a $4.5 million first-half net loss; Lightbridge recognized approximately $3.3 million of its allocated loss.
- Enfission’s 2019–2020 budget and future work scope were still under discussion between the joint-venture partners. Development could be delayed or scaled back until agreement is reached. Management’s near-term targets include surrogate-material full-length rod fabrication, test-reactor sample manufacturing arrangements, and a U.S. utility lead-test-rod agreement, anticipated over the next 12 to 18 months.
- Funding may depend on additional equity or strategic investment, including sales under the 2019 at-the-market (ATM) program. The company sold about 4.7 million shares for approximately $3.1 million gross proceeds in the first half. Subsequent July ATM sales generated approximately $0.9 million net proceeds from about 1.4 million shares. Future financing availability and terms are not assured.
- Key risks include technology development and regulatory approval, commercialization uncertainty, dependence on Framatome and Enfission, capital needs, nuclear-industry regulation and public acceptance, competition, and intellectual-property protection. Management reported no material changes to previously disclosed risk factors.
- A former CFO’s OSHA complaint was dismissed in January 2018, but an appeal was filed in March 2018; the company says it will defend the appeal and expects no adverse finding. It reported no material legal proceedings.
Important facts for investors to verify
- Whether Lightbridge and Framatome agree on Enfission’s budget, funding contributions, and development scope, and whether milestones proceed on the stated timetable.
- Whether projected cash needs, including joint-venture funding and R&D equipment spending, remain within available resources and whether additional financing is required.
- ATM issuance pace, proceeds, and resulting dilution, including the potential conversion and dividend-related shares from preferred stock and other equity awards.
- Evidence of technical progress, regulatory engagement, test-material fabrication, and utility participation; the filing’s performance and safety benefits remain development-stage expectations.
- Resolution of the OSHA appeal and the extent to which insurance covers related legal costs.